Skip to main content

Cogent Biosciences, Inc. (COGT)

NASDAQ: COGT · Delayed Price · USD
8.80 -0.19 (-2.11%)
Sep 20, 2021 4:00 PM EDT - Market closed
Market Cap350.67M
Revenue (ttm)312,000
Net Income (ttm)-194.00M
Shares Out39.85M
EPS (ttm)-7.58
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume159,418
Open8.70
Previous Close8.99
Day's Range8.32 - 9.01
52-Week Range2.20 - 14.44
Betan/a
AnalystsStrong Buy
Price Target19.83 (+125.3%)
Est. Earnings DateNov 9, 2021

About COGT

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies to treat genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. Cogent Biosciences, Inc. has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of CGT9486 and ...

IndustryBiotechnology
IPO DateMar 29, 2018
Employees15
Stock ExchangeNASDAQ
Ticker SymbolCOGT
Full Company Profile

Financial Performance

In 2020, COGT's revenue was $7.87 million, a decrease of -65.02% compared to the previous year's $22.50 million. Losses were -$179.21 million, 463.0% more than in 2019.

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for COGT stock is "Strong Buy." The 12-month stock price forecast is 19.83, which is an increase of 125.34% from the latest price.

Price Target
$19.83
(125.34% upside)
Analyst Consensus: Strong Buy

News

Cogent Biosciences to Present at Wedbush PacGrow Virtual Healthcare Conference 2021

CAMBRIDGE, Mass. and BOULDER, Colo.

1 month ago - PRNewsWire

Cogent Biosciences to Present at Ladenburg Thalmann Virtual Healthcare Conference 2021

CAMBRIDGE, Mass. and BOULDER, Colo.

2 months ago - PRNewsWire

Cogent Biosciences to Present at Jefferies Virtual Healthcare Conference 2021

CAMBRIDGE, Mass. and BOULDER, Colo.

3 months ago - PRNewsWire

Cogent Biosciences Appoints Evan Kearns as Chief Legal Officer

CAMBRIDGE, Mass. and BOULDER, Colo.

4 months ago - PRNewsWire

Cogent Biosciences Announces Creation of Cogent Research Team

BOULDER, Colo. and CAMBRIDGE, Mass.

5 months ago - PRNewsWire

Cogent Biosciences, Inc. (COGT) Reports Q4 Loss, Lags Revenue Estimates

Cogent Biosciences, Inc. (COGT) delivered earnings and revenue surprises of -1910.00% and -100.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for th...

6 months ago - Zacks Investment Research

Cogent Biosciences Reports Fourth Quarter 2020 and Full Year 2020 Financial Results

CAMBRIDGE, Mass., March 16, 2021 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announ...

6 months ago - PRNewsWire

Cogent Biosciences Appoints Accomplished Finance Executive Todd E. Shegog to its Board of Directors

CAMBRIDGE, Mass., Feb. 22, 2021 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announc...

6 months ago - PRNewsWire

Cogent Biosciences to Present at Virtual 10th Annual SVB Leerlink Global Healthcare Conference 2021

CAMBRIDGE, Mass., Feb. 18, 2021 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announc...

7 months ago - PRNewsWire

Cogent Biosciences to Present at LifeSci Partners Virtual Precision Oncology Day 2021

CAMBRIDGE, Mass., Feb. 11, 2021 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announc...

7 months ago - PRNewsWire

Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriter's Op...

CAMBRIDGE, Mass., Dec. 4, 2020 /PRNewswire/ -- Cogent Biosciences, Inc. ("Cogent") (NASDAQ: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, tod...

9 months ago - PRNewsWire

Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock

CAMBRIDGE, Mass., Dec. 1, 2020 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announce...

9 months ago - PRNewsWire

Cogent Biosciences Announces $60.0 Million Public Offering of Shares of Common Stock

CAMBRIDGE, Mass., Nov. 30, 2020 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announc...

9 months ago - PRNewsWire

Cogent Biosciences to Participate in 3rd Annual Evercore ISI HealthCONx Virtual Conference

CAMBRIDGE, Mass., Nov. 20, 2020 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announc...

10 months ago - PRNewsWire

Cogent Biosciences to Present at Jefferies 2020 Virtual London Healthcare Conference

CAMBRIDGE, Mass., Nov. 12, 2020 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announc...

10 months ago - PRNewsWire

Cogent Biosciences Appoints Andrew Robbins as Chief Executive Officer

CAMBRIDGE, Mass., Oct. 26, 2020 /PRNewswire/ -- Cogent Biosciences, Inc. ("Cogent") (NASDAQ: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, to...

10 months ago - PRNewsWire

Unum Therapeutics Announces Company Name Change to Cogent Biosciences, Highlights Recent Scientific and Operational P...

CAMBRIDGE, Mass., Oct. 5, 2020 /PRNewswire/ -- Unum Therapeutics Inc. ("Unum") (NASDAQ: UMRX), a biotechnology company focused on developing precision therapies for genetically defined diseases, today a...

11 months ago - PRNewsWire

Is Unum Therapeutics (UMRX) Stock Outpacing Its Medical Peers This Year?

Is (UMRX) Outperforming Other Medical Stocks This Year?

1 year ago - Zacks Investment Research

Unum Therapeutics Transfers BOXR Cell-Based Therapy Technology to SOTIO

CAMBRIDGE, Mass., Aug. 31, 2020 /PRNewswire/ -- Unum Therapeutics Inc.

1 year ago - PRNewsWire

Unum Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Updates

CAMBRIDGE, Mass., Aug. 11, 2020 /PRNewswire/ -- Unum Therapeutics Inc.

1 year ago - PRNewsWire

Nasdaq Tops 11,000: 5 Best Stocks With Room for More Upside

On Aug 6, the Nasdaq Composite Index topped the milestone of 11,000. The tech-heavy laden completed its 1000-point journey in 40 trading days, representing the fastest ever rise in 20 years.

Other symbols:KOPNNVAXQDELVERI
1 year ago - Zacks Investment Research

Is Unum Therapeutics (UMRX) Outperforming Other Medical Stocks This Year?

Is (UMRX) Outperforming Other Medical Stocks This Year?

1 year ago - Zacks Investment Research

Unum Therapeutics Inc. (UMRX) Outpaces Stock Market Gains: What You Should Know

Unum Therapeutics Inc. (UMRX) closed the most recent trading day at $2.74, moving +1.86% from the previous trading session.

1 year ago - Zacks Investment Research